Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 2/20 | 0.33 |
| ▸ | FEN1 | P39748 | 2/20 | 0.33 |
| ▸ | FPR2 | P25090 | 3/20 | 0.33 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.32 |
| ▸ | SERPINA2 | P20848 | 1/20 | 0.30 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
| ▸ | PRKDC | P78527 | 1/20 | 0.30 |
| ▸ | ATR | Q13535 | 1/20 | 0.30 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13586495 | 1.00 | ALOX5AP (0.33) | ALOX5APFEN1FPR2TUBB1FGFR1 | |
| SCHEMBL14766334 | 0.92 | FGFR1 (0.32) | ALOX5APFEN1FPR2TUBB1FGFR1 | |
| SCHEMBL14765704 | 0.92 | FGFR1 (0.32) | ALOX5APFEN1FPR2TUBB1FGFR1 | |
| SCHEMBL12739357 | 0.91 | FPR2 (0.32) | ALOX5APFEN1FPR2TUBB1FGFR1 | |
| SCHEMBL12734384 | 0.91 | FPR2 (0.32) | ALOX5APFEN1FPR2TUBB1FGFR1 | |
| SCHEMBL12716435 | 0.91 | NFE2L2 (0.35) | ALOX5APFEN1FPR2TUBB1 | |
| SCHEMBL12822086 | 0.91 | NFE2L2 (0.35) | ALOX5APFEN1FPR2TUBB1 | |
| SCHEMBL12739342 | 0.90 | FPR2 (0.31) | ALOX5APFEN1FPR2TUBB1FGFR1 | |
| SCHEMBL12734370 | 0.90 | FPR2 (0.31) | ALOX5APFEN1FPR2TUBB1FGFR1 | |
| SCHEMBL12739355 | 0.89 | FPR2 (0.33) | ALOX5APFEN1FPR2TUBB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394294-B2 | Four-ring liquid crystal compound having lateral fluorine, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-03-12 | — | — | US | disclosed |
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | ALOX5AP 1673/4885FEN1 3340/4885FPR2 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.